
PU-139
CAS No. 158093-65-3
PU-139 ( PU139 | PU 139 )
产品货号. M12258 CAS No. 158093-65-3
PU-139 是一种有效的、非选择性的 HAT(组蛋白乙酰转移酶)抑制剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥988 | 有现货 |
![]() ![]() |
10MG | ¥1725 | 有现货 |
![]() ![]() |
25MG | ¥3750 | 有现货 |
![]() ![]() |
50MG | ¥5411 | 有现货 |
![]() ![]() |
100MG | ¥7549 | 有现货 |
![]() ![]() |
500MG | ¥15066 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称PU-139
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述PU-139 是一种有效的、非选择性的 HAT(组蛋白乙酰转移酶)抑制剂。
-
产品描述PU-139 is a potent, unselective HAT (Histone acetyltransferase) inhibitor that blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB protein (CBP) and p300; triggers caspase-independent cell death in cell culture, blocks growth of SK-N-SH neuroblastoma xenografts in mice, and synergizes the effect of doxorubicin in vivo.
-
体外实验PU139 inhibits cell growth with GI50s of <60 μM (A431, A549, A2780, HepG2, SW480, U-87?MG, HCT116 and SK-N-SH and MCF7 cells).PU139 (0-100 μM; 24-72 hours) triggers caspase-independent cell death in the neuroblastoma cell line SK-N-SH.
-
体内实验PU139 (25 mg/kg; i.p.) synergizes with Doxorubicin used as a prototypic chemotherapeutic drug in growth inhibition. Animal Model:Male NMRI:nu/nu mice (Neuroblastoma xenografts) Dosage:25 mg/kg Administration:Intraperitoneally (PU139) with Dxorubicin at 8?mg/kg i.v.; Administered on days 14 and 21 as a single dose of each compound or, for combination therapy; both drugs were administered successively within 1?h. Result:Optimum growth inhibition following a single PU139 therapy was moderate, but significant as compared with the untreated group and confirmed the previous findings.
-
同义词PU139 | PU 139
-
通路Chromatin/Epigenetic
-
靶点HAT
-
受体HAT
-
研究领域——
-
适应症——
化学信息
-
CAS Number158093-65-3
-
分子量246.259
-
分子式C12H7FN2OS
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 10 mg/mL (40.61 mM)
-
SMILESO=C1N(C2=CC=C(F)C=C2)SC3=NC=CC=C31
-
化学全称2-(4-fluorophenyl)isothiazolo[5,4-b]pyridin-3(2H)-one
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Gajer JM, et al. Oncogenesis. 2015 Feb 9;4:e137.
2. Carneiro VC, et al. PLoS Pathog. 2014 May 8;10(5):e1004116.
3. Furdas SD, et al. Bioorg Med Chem. 2011 Jun 15;19(12):3678-89.